Sun YT, Chen QQ. Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients. World J Hepatol 2024; 16(1): 109-111 [PMID: 38313247 DOI: 10.4254/wjh.v16.i1.109]
Corresponding Author of This Article
Qian-Qian Chen, MD, Associate Chief Physician, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100193, China. qian_qian_chen@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jan 27, 2024; 16(1): 109-111 Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.109
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
Yu-Tong Sun, Qian-Qian Chen
Yu-Tong Sun, Qian-Qian Chen, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100193, China
Author contributions: Sun YT drafted the article; Chen QQ made critical revisions related to important intellectual content of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian-Qian Chen, MD, Associate Chief Physician, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100193, China. qian_qian_chen@163.com
Received: October 30, 2023 Peer-review started: October 30, 2023 First decision: November 22, 2023 Revised: December 4, 2023 Accepted: January 12, 2024 Article in press: January 12, 2024 Published online: January 27, 2024
Abstract
This letter comments on the article which reported that tenofovir alafenamide may increase blood lipid levels compared with entecavir in patients with chronic hepatitis B published on World J Hepatol 2023 August 27. We review the related research content, topic selection, methodology, conclusions, strengths and weaknesses of this article. And evaluate it in relation to other published relevant articles.
Core Tip: With the significant increase in the incidence of nonalcoholic fatty liver disease (NAFLD) in China, the number of patients with co-morbid chronic hepatitis B (CHB) and NAFLD has gradually increased. This letter comments on a published study which showned that CHB patients treated with tenofovir alafenamide (TAF) had higher levels of total cholesterol than CHB patients treated with entecavir; however, TAF-induced dyslipidemia did not increase the incidence of NAFLD. We comment on the article.
